-- Preview Email Newsletter
| Milk Newsletter for 2024-10-30 ( 3 items ) |
|
Bovine H5N1 Influenza From Infected Worker Transmissible and Lethal in Animal Models (10)
WASHINGTON, Oct. 29 -- The U.S. Department of Health and Human Services' National Institute of Allergy and Infectious Diseases issued the following news release:
* * *
Some Antiviral Drugs Highly Effective Against Bovine H5N1
* * *
A highly pathogenic avian influenza (HPAI) H5N1 virus, isolated from the eye of a farm worker who became infected through contact with dairy cows, was lethal in mice and ferrets infected in a high-containment laboratory environment, according to a new study in Nat more PR
Everyday Ut Prosim: How Hokies serve after Hurricane Helene (10)
BLACKSBURG, Virginia, Oct. 29 -- Virginia Tech issued the following news:
The Everyday Ut Prosim series celebrates how Hokies live out the spirit of service on campus and off a spirit that ignited after Hurricane Helene hit the area on Sept. 27. Since then, students, staff, and faculty have mobilized to provide service to affected communities in Virginia, North Carolina, and Tennessee. Here are a few of their stories.
"I'm not going to go empty handed"
When a musician friend invited Scott Pat more PR
Johnson and Johnson: Tremfya is the First and Only IL-23 Inhibitor to Demonstrate Robust Results With a Fully Subcutaneous Regimen in Both Induction and Maintenance in Crohn's Disease (10)
NEW BRUNSWICK, New Jersey, Oct. 29 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
A greater number of patients treated with subcutaneous TREMFYA induction and maintenance achieved clinical and endoscopic remission at 48 weeks in the Phase 3 GRAVITI study versus placebo
TREMFYA could become the first IL-23 treatment to offer both a subcutaneous and intravenous (IV) induction regimen for patients living with Crohn's disease (CD), pending FDA approval
* * *
PHILADELPH more PR
|